Interestingly, indices of the concentration of glial fibrillary acidic protein (GFAP), a sensitive and reliable marker of most, if not all, reactive astrocytes during brain disease, demonstrate high correlations with MAO-B binding in the primary regions assessed across postmortem investigations in Alzheimer’s disease, multisystem atrophy, progressive supranuclear palsy, and amyotrophic lateral sclerosis (Ekblom et al., 1993; Saura et al., 1994; Tong et al., 2017). This evidence concerns the gene GFAP and progressive supranuclear palsy.